vs

Side-by-side financial comparison of First Foundation Inc. (FFWM) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $48.4M, roughly 1.5× First Foundation Inc.). First Foundation Inc. runs the higher net margin — -97.9% vs -121.9%, a 24.0% gap on every dollar of revenue. On growth, First Foundation Inc. posted the faster year-over-year revenue change (421.7% vs -6.2%). Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $-35.2M). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -2.7%).

John B. Lacson Colleges Foundation (Bacolod), Inc. is a private maritime college in Bacolod, Negros Occidental, Philippines.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

FFWM vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.5× larger
HCAT
$74.7M
$48.4M
FFWM
Growing faster (revenue YoY)
FFWM
FFWM
+427.9% gap
FFWM
421.7%
-6.2%
HCAT
Higher net margin
FFWM
FFWM
24.0% more per $
FFWM
-97.9%
-121.9%
HCAT
More free cash flow
HCAT
HCAT
$44.9M more FCF
HCAT
$9.6M
$-35.2M
FFWM
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-2.7%
FFWM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FFWM
FFWM
HCAT
HCAT
Revenue
$48.4M
$74.7M
Net Profit
$-8.0M
$-91.0M
Gross Margin
Operating Margin
-97.5%
-115.3%
Net Margin
-97.9%
-121.9%
Revenue YoY
421.7%
-6.2%
Net Profit YoY
43.0%
-340.3%
EPS (diluted)
$-0.09
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FFWM
FFWM
HCAT
HCAT
Q4 25
$48.4M
$74.7M
Q3 25
$63.6M
$76.3M
Q2 25
$51.4M
$80.7M
Q1 25
$71.4M
$79.4M
Q4 24
$9.3M
$79.6M
Q3 24
$9.2M
$76.4M
Q2 24
$57.5M
$75.9M
Q1 24
$51.1M
$74.7M
Net Profit
FFWM
FFWM
HCAT
HCAT
Q4 25
$-8.0M
$-91.0M
Q3 25
$-146.3M
$-22.2M
Q2 25
$-7.7M
$-41.0M
Q1 25
$6.9M
$-23.7M
Q4 24
$-14.1M
$-20.7M
Q3 24
$-82.2M
$-14.7M
Q2 24
$3.1M
$-13.5M
Q1 24
$793.0K
$-20.6M
Gross Margin
FFWM
FFWM
HCAT
HCAT
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
FFWM
FFWM
HCAT
HCAT
Q4 25
-97.5%
-115.3%
Q3 25
-92.7%
-22.9%
Q2 25
-21.1%
-46.0%
Q1 25
8.8%
-25.4%
Q4 24
-247.7%
-22.0%
Q3 24
-1276.7%
-17.9%
Q2 24
4.6%
-20.8%
Q1 24
-0.2%
-30.5%
Net Margin
FFWM
FFWM
HCAT
HCAT
Q4 25
-97.9%
-121.9%
Q3 25
-230.1%
-29.1%
Q2 25
-15.0%
-50.8%
Q1 25
9.7%
-29.9%
Q4 24
-152.2%
-26.0%
Q3 24
-896.9%
-19.3%
Q2 24
5.4%
-17.8%
Q1 24
1.6%
-27.6%
EPS (diluted)
FFWM
FFWM
HCAT
HCAT
Q4 25
$-0.09
$-1.29
Q3 25
$-1.78
$-0.32
Q2 25
$-0.09
$-0.59
Q1 25
$0.08
$-0.35
Q4 24
$-0.24
$-0.33
Q3 24
$-1.23
$-0.24
Q2 24
$0.05
$-0.23
Q1 24
$0.01
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FFWM
FFWM
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$1.6B
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$912.6M
$245.8M
Total Assets
$11.9B
$502.6M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FFWM
FFWM
HCAT
HCAT
Q4 25
$1.6B
$95.7M
Q3 25
$1.7B
$91.5M
Q2 25
$1.1B
$97.3M
Q1 25
$1.0B
$342.0M
Q4 24
$1.0B
$392.0M
Q3 24
$1.1B
$387.3M
Q2 24
$1.4B
$308.3M
Q1 24
$1.6B
$327.8M
Total Debt
FFWM
FFWM
HCAT
HCAT
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
FFWM
FFWM
HCAT
HCAT
Q4 25
$912.6M
$245.8M
Q3 25
$917.9M
$331.9M
Q2 25
$1.1B
$347.5M
Q1 25
$1.1B
$376.8M
Q4 24
$1.1B
$365.2M
Q3 24
$1.1B
$355.0M
Q2 24
$933.2M
$357.0M
Q1 24
$928.7M
$357.2M
Total Assets
FFWM
FFWM
HCAT
HCAT
Q4 25
$11.9B
$502.6M
Q3 25
$11.9B
$587.1M
Q2 25
$11.6B
$616.2M
Q1 25
$12.6B
$891.5M
Q4 24
$12.6B
$858.9M
Q3 24
$13.4B
$813.0M
Q2 24
$13.7B
$691.7M
Q1 24
$13.6B
$695.1M
Debt / Equity
FFWM
FFWM
HCAT
HCAT
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FFWM
FFWM
HCAT
HCAT
Operating Cash FlowLast quarter
$-31.9M
$9.9M
Free Cash FlowOCF − Capex
$-35.2M
$9.6M
FCF MarginFCF / Revenue
-72.8%
12.9%
Capex IntensityCapex / Revenue
6.9%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-45.9M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FFWM
FFWM
HCAT
HCAT
Q4 25
$-31.9M
$9.9M
Q3 25
$9.2M
$-464.0K
Q2 25
$-16.3M
$-9.0M
Q1 25
$-552.0K
$280.0K
Q4 24
$-8.7M
$-3.5M
Q3 24
$14.2M
$6.2M
Q2 24
$-9.1M
$1.6M
Q1 24
$7.2M
$10.3M
Free Cash Flow
FFWM
FFWM
HCAT
HCAT
Q4 25
$-35.2M
$9.6M
Q3 25
$8.6M
$-719.0K
Q2 25
$-16.7M
$-9.2M
Q1 25
$-2.5M
$-390.0K
Q4 24
$-11.4M
$-3.9M
Q3 24
$13.4M
$5.5M
Q2 24
$-9.4M
$1.3M
Q1 24
$5.9M
$10.1M
FCF Margin
FFWM
FFWM
HCAT
HCAT
Q4 25
-72.8%
12.9%
Q3 25
13.5%
-0.9%
Q2 25
-32.4%
-11.4%
Q1 25
-3.5%
-0.5%
Q4 24
-123.5%
-4.9%
Q3 24
146.2%
7.2%
Q2 24
-16.3%
1.7%
Q1 24
11.6%
13.5%
Capex Intensity
FFWM
FFWM
HCAT
HCAT
Q4 25
6.9%
0.4%
Q3 25
1.0%
0.3%
Q2 25
0.8%
0.3%
Q1 25
2.8%
0.8%
Q4 24
29.4%
0.5%
Q3 24
9.0%
0.9%
Q2 24
0.4%
0.4%
Q1 24
2.5%
0.3%
Cash Conversion
FFWM
FFWM
HCAT
HCAT
Q4 25
Q3 25
Q2 25
Q1 25
-0.08×
Q4 24
Q3 24
Q2 24
-2.96×
Q1 24
9.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FFWM
FFWM

Segment breakdown not available.

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons